193 related articles for article (PubMed ID: 25243629)
1. Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation.
Israyelyan A; Goldstein L; Tsai W; Aquino L; Forman SJ; Nakamura R; Diamond DJ
Bone Marrow Transplant; 2015 Jan; 50(1):26-33. PubMed ID: 25243629
[TBL] [Abstract][Full Text] [Related]
2. Wilms tumor gene 1 expression as a predictive marker for relapse and survival after hematopoietic stem cell transplantation for myelodysplastic syndromes.
Yoon JH; Jeon YW; Yahng SA; Shin SH; Lee SE; Cho BS; Lee DG; Eom KS; Kim HJ; Lee S; Min CK; Cho SG; Kim Y; Kim DW; Lee JW; Han K; Min WS; Park CW; Kim M; Kim YJ
Biol Blood Marrow Transplant; 2015 Mar; 21(3):460-7. PubMed ID: 25460359
[TBL] [Abstract][Full Text] [Related]
3. Poor correlation of kinetics between BCR-ABL and WT1 transcript levels after allogeneic stem cell transplantation.
Uzunel M; Ringdén O
Bone Marrow Transplant; 2004 Jan; 33(1):47-52. PubMed ID: 14704656
[TBL] [Abstract][Full Text] [Related]
4. Wilms' Tumor 1 Gene Expression Using a Standardized European LeukemiaNet-Certified Assay Compared to Other Methods for Detection of Minimal Residual Disease in Myelodysplastic Syndrome and Acute Myelogenous Leukemia after Allogeneic Blood Stem Cell Transplantation.
Rautenberg C; Pechtel S; Hildebrandt B; Betz B; Dienst A; Nachtkamp K; Kondakci M; Geyh S; Wieczorek D; Haas R; Germing U; Kobbe G; Schroeder T
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2337-2343. PubMed ID: 29753838
[TBL] [Abstract][Full Text] [Related]
5. Associations between the peripheral blood Wilms tumor gene 1 level and both bone marrow blast cells and the prognosis in patients with myelodysplastic syndrome.
Mashima K; Ikeda T; Toda Y; Ito S; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Fujiwara S; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Leuk Lymphoma; 2019 Mar; 60(3):703-710. PubMed ID: 30188227
[TBL] [Abstract][Full Text] [Related]
6. Clinical Utility of Wilms' Tumor 1 Monitoring in Patients with Myeloid Malignancy and Prior Allogeneic Hematopoietic Stem Cell Transplantation.
Ino K; Fuji S; Tajima K; Tanaka T; Okinaka K; Inamoto Y; Kurosawa S; Kim SW; Katayama N; Fukuda T
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1780-1787. PubMed ID: 28673850
[TBL] [Abstract][Full Text] [Related]
7. Wilms' tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia.
Messina C; Candoni A; Carrabba MG; Tresoldi C; Sala E; Tassara M; Crippa A; Peccatori J; Assanelli A; Gattillo S; Bellio L; Fanin R; Ciceri F; Bernardi M
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1586-91. PubMed ID: 24954546
[TBL] [Abstract][Full Text] [Related]
8. Wilms' tumor-1 transcript in peripheral blood helps diagnose acute myeloid leukemia and myelodysplastic syndrome in patients with pancytopenia.
Yamauchi T; Matsuda Y; Takai M; Tasaki T; Hosono N; Negoro E; Ikegaya S; Takagi K; Kishi S; Yoshida A; Urasaki Y; Ueda T
Anticancer Res; 2012 Oct; 32(10):4479-83. PubMed ID: 23060576
[TBL] [Abstract][Full Text] [Related]
9. WT1 Expression in Circulating RNA as a Minimal Residual Disease Marker for AML Patients After Stem-Cell Transplantation.
Zhong L; Wei L; Chen J; Huang X; Gong Y; Lu Y
Mol Diagn Ther; 2015 Aug; 19(4):205-12. PubMed ID: 26138637
[TBL] [Abstract][Full Text] [Related]
10. The Proportional Relationship Between Pretransplant WT1 mRNA Levels and Risk of Mortality After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Not in Remission.
Ido K; Nakamae M; Koh H; Okamura H; Nanno S; Nishimoto M; Takeoka Y; Hirose A; Nakashima Y; Hashimoto Y; Nakane T; Hino M; Nakamae H
Transplantation; 2019 Oct; 103(10):2201-2210. PubMed ID: 30801534
[TBL] [Abstract][Full Text] [Related]
11. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia.
Ogawa H; Tamaki H; Ikegame K; Soma T; Kawakami M; Tsuboi A; Kim EH; Hosen N; Murakami M; Fujioka T; Masuda T; Taniguchi Y; Nishida S; Oji Y; Oka Y; Sugiyama H
Blood; 2003 Mar; 101(5):1698-704. PubMed ID: 12406915
[TBL] [Abstract][Full Text] [Related]
12. Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation.
Casalegno-Garduño R; Schmitt A; Spitschak A; Greiner J; Wang L; Hilgendorf I; Hirt C; Ho AD; Freund M; Schmitt M
Int J Cancer; 2016 Apr; 138(7):1792-801. PubMed ID: 26519872
[TBL] [Abstract][Full Text] [Related]
13. Role of Sequential Monitoring of WT1 Gene Expression in Patients With Acute Myeloid Leukemia for the Early Detection of Leukemia Relapse.
Mashima K; Oh I; Ikeda T; Toda Y; Ito S; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Fujiwara SI; Hatano K; Sato K; Omine K; Muroi K; Kanda Y
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e521-e527. PubMed ID: 30181104
[TBL] [Abstract][Full Text] [Related]
14. WT1 mRNA level in peripheral blood is a sensitive biomarker for monitoring minimal residual disease in acute myeloid leukemia.
Sakamoto Y; Mariya Y; Sasaki S; Teshiromori R; Oshikiri T; Segawa M; Ogura K; Akagi T; Kubo K; Kaimori M; Funato T
Tohoku J Exp Med; 2009 Oct; 219(2):169-76. PubMed ID: 19776535
[TBL] [Abstract][Full Text] [Related]
15. Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value.
Nomdedéu JF; Esquirol A; Carricondo M; Pratcorona M; Hoyos M; Garrido A; Rubio M; Bussaglia E; García-Cadenas I; Estivill C; Brunet S; Martino R; Sierra J
Biol Blood Marrow Transplant; 2018 Jan; 24(1):55-63. PubMed ID: 28939453
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of WT1 expression prior to hematopoietic stem cell transplantation in children with malignant hematological diseases.
Woehlecke C; Wittig S; Arndt C; Gruhn B
J Cancer Res Clin Oncol; 2015 Mar; 141(3):523-9. PubMed ID: 25238704
[TBL] [Abstract][Full Text] [Related]
17. Cross-sectional monitoring of Wilms' tumor gene 1 (WT1) expression in Iranian patients with acute lymphoblastic leukemia at diagnosis, relapse and remission.
Asgarian Omran H; Shabani M; Vossough P; Sharifian R; Tabrizi M; Khoshnoodi J; Jeddi-Tehrani M; Rabbani H; Shokri F
Leuk Lymphoma; 2008 Feb; 49(2):281-90. PubMed ID: 18231915
[TBL] [Abstract][Full Text] [Related]
18. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome.
Bergmann L; Miething C; Maurer U; Brieger J; Karakas T; Weidmann E; Hoelzer D
Blood; 1997 Aug; 90(3):1217-25. PubMed ID: 9242555
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning.
Lange T; Hubmann M; Burkhardt R; Franke GN; Cross M; Scholz M; Leiblein S; Al-Ali HK; Edelmann J; Thiery J; Niederwieser D
Leukemia; 2011 Mar; 25(3):498-505. PubMed ID: 21135860
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Mo XD; Qin YZ; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Ann Hematol; 2016 Aug; 95(8):1233-40. PubMed ID: 27302479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
